Interestingly, NTRK2 inhibitors such as entrectinib significantly reduced the proliferation of glioma cells in vitro. BDNF-NTRK2 signaling axis is a prime example of how glioma cells reinvent neural plasticity during tumor progression (Table 1). This evidence concerns the gene NTRK2 and neoplasm.